Published in:
01-12-2016 | Letter to the Editor
Improvement in hereditary hemorrhagic telangiectasia after treatment with the multi-kinase inhibitor Sunitinib
Published in: Annals of Hematology | Issue 12/2016
Login to get accessExcerpt
Dear Editor, (Table 1).
Table 1
Retrospective assessment of epistaxis severity before medication with Sunitinib, during treatment with Sunitinib, and during the off treatment period (dose of Sunitinib—37.5 mg for 4 weeks followed by 2 weeks off treatment)
|
Before Sunitinib
|
During Sunitinib treatment
|
During off-treatment period
|
|
|---|---|---|---|
|
Observational period
|
Several years
|
5 monthsa
|
2 weeksa
|
|
Epistaxis frequency (times/month)
|
30
|
2
|
4
|
|
Average duration [min]
|
30
|
3
|
3
|
|
Longest duration [min]
|
90
|
3
|
3
|
|
Intensityb
|
10
|
1
|
2
|
|
Time lost per day due to nosebleeds [min]c
|
30
|
3
|
3
|
|
Subjective impedimentd
|
Crippled
|
None
|
None
|
|
Method used to collect the blood
|
Fully soaked handkerchief
|
Slightly stained handkerchief
|
Slightly stained handkerchief
|
|
Estimated blood loss [ml]
|
50
|
<5
|
<5
|
|
Normalized Epistaxis Severity Score (ESS)
|
7.46
|
1.41
|
1.92
|
|
Interpretation suggested by ESS
|
Severe
|
Mild
|
Mild
|
|
CTCAEe
|
2
|
1
|
1
|